Search results: (10000)
News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency
Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.
News Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.
News Interactive Case Study: AATD – Alpha-1-Antitrypsin Deficiency
We present a case study of a man who was 41 years old at the time of his first contact with a pulmonary doctor. He came with symptoms of allergic seasonal rhinoconjunctivitis, proven sensitivity to spring trees, grasses, and dust mites, otherwise healthy, a parrot breeder. He is a former smoker with a smoking history of 20 pack-years. He was examined for exertional dyspnea, cough, recurrent respiratory infections, and wheezing. Try to follow the further diagnostic procedure and considerations with us, where you can choose between different options. At the same time, you will verify whether you proceeded correctly, along with the justification for the step taken.
News Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients
The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life are highly heterogeneous. This contribution by pulmonologist Robert Sandhaus summarizes interesting findings from studies on the quality of life of patients with this disease and the factors influencing it.
News How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
News New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference abstracts to its real-world application in clinical practice, the new recommendations of the European Society for Medical Oncology (ESMO) describe the examination of circulating tumor DNA from peripheral blood.
News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting
Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
News Analysis of the Benefits and Risks of Superabsorbent Dressings in the Treatment of Moderate to Highly Exuding Leg Ulcers
A study on the benefits and risks of superabsorbent dressings compared to standard dressings in the treatment of moderate to highly exuding leg ulcers was published last year in The International Journal of Lower Extremity Wounds.
News Can the use of sartans reduce mortality and severity of COVID-19 in hypertensives?
Existing scientific and clinical evidence suggests the involvement of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of COVID-19. Some of the initial experimental therapy proposals included various interventions in the RAAS.
News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
News How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?
One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the relationship between uric acid levels and the incidence of cardiorenal events in type 2 diabetics with existing cardiovascular disease.
News Long-Term Effect of Nuclear Magnetic Resonance Therapy on Osteoarthritis – An Unconventional Case Report
Osteoarthritis is among the most common health issues in adults, with its prevalence increasing with advancing age. There is currently no causal therapy for the disease; hence, the standard approach is symptomatic treatment with surgical joint reconstruction in advanced stages of the disease. The presented case report describes a successful case of long-term therapy for osteoarthritis using molecular biophysical stimulation.
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?
News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis
What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC).
.
News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan
Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.
News Longer survival without liver transplant in patients with PBC treated with OCA?
Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
News Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device
Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized recommendations for anticoagulant therapy during the postoperative period. One option to bridge the time until therapeutic INR is achieved after LVAD implantation is the low molecular weight heparin (LMWH) enoxaparin, which was investigated for its efficacy and safety in this indication by experts from Kansas, USA, cited in the following study.
News Polatuzumab Vedotin in the Treatment of NHL - News from the 25th EHA Congress
Polatuzumab vedotin (Polivy) is approved in the EU for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), for whom hematopoietic stem cell transplantation (HSCT) is not suitable. We provide an overview of the latest news regarding the role of this modern medicine in the therapy of non-Hodgkin's lymphomas (NHL), presented at the 25th Congress of the European Hematology Association (EHA), held virtually due to the pandemic situation.
News Addition of ixazomib to lenalidomide and dexamethasone in multiple myeloma − Data from real-world Czech practice
A group of Czech and Slovak experts led by Associate Professor Jiří Minařík from the Hemato-Oncology Clinic of the Faculty of Medicine UP and University Hospital Olomouc published the final results of an observational study evaluating the addition of ixazomib to the combination with lenalidomide and dexamethasone in patients with relapsing/refractory multiple myeloma (RRMM). This involves experiences from real clinical practice, with data obtained from the Czech Registry of Monoclonal Gammopathies.
News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma
Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.
News New Treatment Options for Hemophilia Come with Discussions on Important Issues
The organizing committee of this year's virtual congress of the European Association for Haemophilia and Allied Disorders (EAHAD 2021) promised in the opening speech a "showcase of the latest innovations and advances in the field of hemophilia and bleeding disorders." The program naturally included discussions on current research findings and practical experiences. Topics included the potential role of coagulation factor VIII even with non-factor therapies and the importance of monitoring the success of new therapeutic approaches.
News ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?
In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic obstructive pulmonary disease (COPD) and its acute exacerbations (COPD AE). This topic was also well-represented in the e-poster presentations section. From that section, we select 3 studies whose conclusions are summarized below.
News Acquired Hemophilia A Newly Diagnosed in an Elderly Patient − A Case Report
At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.
News Efficacy and Safety of Two Pharmacokinetically-Driven Prophylactic Regimens in People with Hemophilia A
Standard prophylaxis for bleeding in hemophilia A, based on the administration of coagulation factor VIII (FVIII), depends on the patient's weight, the severity of the coagulation factor deficiency, and the nature of bleeding episodes. The current trend, however, is an individualized approach in prophylaxis, which can improve clinical outcomes and optimize bleeding disorder therapy. A clinical study evaluated the efficacy and safety of two prophylactic regimens with different target trough levels of FVIII.